MAPK3 and schwannoma: While Ras activation is decreased at low nilotinib concentrations, there is no significant effect on ERK1/2 phosphorylation, which is in part explained by the presence of non-PDGFR-mediated means of activating ERK1/2, as previously described in schwannomas [9].